A 23-valent polysaccharide vaccine against disease caused by Streptococcus pneumoniae
(pneumococcus) was licensed in the United States in 1983. It replaces the 14-valent …

Objective.—To determine pneumococcal polysaccharide vaccine efficacy in selected
populations at risk for serious pneumococcal infection for whom vaccination is currently …

Trials to determine efficacy of pneumococcal vaccine prior to its licensure resulted in
estimates of efficacy of 76%–100%. However, the populations studied in these trials were …

Contemporary 14-valent pneumococcal polysaccharide vaccine was first licensed in 1977 in
the United States, where about four million doses of vaccine have been distributed to date …

This report updates the last recommendations by the Advisory Committee on Immunization
Practices (ACIP) concerning pneumococcal polysaccharide vaccine (MMWR 1989; 38: 64-8 …

This report updates the last recommendations by the Advisory Committee on Immunization
Practices (ACIP) concerning pneumococcal polysaccharide vaccine (MMWR 1989; 38: 64-8 …

This survey describes patterns of pneumococcal polysaccharide vaccine use, vaccine
registration, vaccination recommendations, and reimbursement for vaccination in the United …

Six years have elapsed since a polyvalent vaccine of pneumococcal capsular
polysaccharides was licensed in the United States for the second time in three decades1; …

Background. Although the protective efficacy of pneumococcal polysaccharide vaccine has
been demonstrated in randomized trials in young African gold miners, there has been …

The capsular polysaccharide pneumococcal vaccine approved by the Food and Drug
Administration in November 1977 has been recommended for persons older than 2 years …